RecruitingNot ApplicableNCT03117946
Modulation of Anti-tumor T Cell Responses in Cancer Patients Treated by Concomitant Radiochemotherapy
Sponsor
Centre Hospitalier Universitaire de Besancon
Enrollment
220 participants
Start Date
May 29, 2017
Study Type
INTERVENTIONAL
Conditions
Summary
The aim of this study is to evaluate modulation of anti-tumor T cell responses in cancer patients treated by concomitant radiochemotherapy (i-RTCT)
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Histologically confirmed NSCLC (Non Small Cell Lung Cancer) or SCLC (small cell lung cancer) OR histologically confirmed Head and neck cancer
- Patient candidate to a first-line concomitant radiochemotherapy
- Written informed consent
Exclusion Criteria6
- Sequential radiochemotherapy, exclusive radiotherapy, or stereotactic radiotherapy
- History of adjuvant radiochemotherapy for cancer treatment
- Patients under immunotherapy, chemotherapy or other immunosuppressive drugs (prednisone or prednisolone ≤ 10 mg/day is allowed)
- HIV, hepatitis C or B virus
- Patients with any medical or psychiatric condition or disease,
- Patients under guardianship, curatorship or under the protection of justice.
Interventions
OTHERBiological samples
blood and tumor tissue sample
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03117946
Related Trials
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT046786483 locations
Virtual Agent Feasibility in Oncology Patients (NTT Data)
NCT066820131 location
Empathic Communication Skills (ECS) Training
NCT0545684112 locations
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT0661828763 locations
Study of Novel Treatment Combinations in Patients With Lung Cancer
NCT05633667100 locations